Gene info: ID 4893

Gene: NRAS

GENE ID: 4893

Description: NRAS proto-oncogene, GTPase

Gene type: protein-coding

Location: 1p13.2

dbXrefs: Ensembl:ENSG00000213281 MIM:164790 Vega:OTTHUMG00000012059 UniprotKB:P01111

RefSeq: NG_007572.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND|AD

# Publications: 21

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 6.821e-1 (AD) 8.207e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
BZW1	0.921
UBE2J1	0.911
DDX18	0.896
GALNT1	0.891
TM9SF3	0.887
PPP6C	0.887
ABCE1	0.885
UBE2A	0.885
TMED2	0.884
SUZ12	0.884

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.625
OR4F29	-0.601
MMP23B	-0.225
ADAMTSL5	-0.178
NXNL1	-0.177
LCN1	-0.17
CXorf67	-0.169
EPPIN	-0.169
RSPO1	-0.159
SPRR2A	-0.156

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of NRAS mRNA"	21346803
C046508	2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone	"NRAS protein mutant form inhibits the reaction [2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone results in increased expression of DUSP1 mRNA]"	8758915
C046508	2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone	"NRAS protein mutant form inhibits the reaction [2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone results in increased expression of FOS mRNA]"	8758915
C029955	2-nitrotoluene	2-nitrotoluene results in increased expression of NRAS mRNA	16460773
C041594	4-nonylphenol	4-nonylphenol results in increased expression of NRAS mRNA	18248853
C542662	AC 93253	AC 93253 results in decreased expression of NRAS mRNA	25912555
D000082	Acetaminophen	Acetaminophen results in decreased expression of NRAS mRNA	21420995
D000082	Acetaminophen	Acetaminophen affects the expression of NRAS mRNA	17562736
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of NRAS mRNA	16483693
D001151	Arsenic	Arsenic results in increased expression of NRAS mRNA	19945496
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of NRAS mRNA"	18567617
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of NRAS protein"	18567617
D004958	Estradiol	Estradiol results in increased expression of NRAS mRNA	23094148
D004958	Estradiol	IGF1R mutant form inhibits the reaction [Estradiol results in increased expression of NRAS mRNA]	23094148
C477843	bicyclol	bicyclol inhibits the reaction [Diethylnitrosamine results in increased expression of NRAS mRNA]	17106253
C006780	bisphenol A	bisphenol A affects the expression of NRAS mRNA	21786754
C006780	bisphenol A	bisphenol A results in increased expression of NRAS mRNA	18248853
C006780	bisphenol A	bisphenol A affects the expression of NRAS mRNA	25181051
C099813	bromochloroacetic acid	bromochloroacetic acid results in increased expression of NRAS mRNA	16460773
D002084	Butylated Hydroxytoluene	Butylated Hydroxytoluene results in increased activity of NRAS	3040652
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of NRAS protein	23811327
D002220	Carbamazepine	Carbamazepine affects the expression of NRAS mRNA	24752500
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in decreased expression of NRAS mRNA	23650126
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of NRAS mRNA	18668222
D002794	Choline	Choline inhibits the reaction [Sodium Fluoride results in decreased expression of NRAS mRNA]	27664006
D003300	Copper	[Disulfiram binds to Copper] which results in decreased expression of NRAS mRNA	24690739
D019327	Copper Sulfate	Copper Sulfate results in increased expression of NRAS mRNA	19549813
C032282	COPP protocol	COPP protocol affects the expression of NRAS mRNA	9427043
C057862	cyanoginosin LR	cyanoginosin LR results in increased expression of NRAS mRNA	28062358
C057862	cyanoginosin LR	cyanoginosin LR results in increased expression of NRAS protein	28062358
C057862	cyanoginosin LR	cyanoginosin LR results in increased expression of NRAS mRNA	17654400
D016572	Cyclosporine	Cyclosporine results in increased expression of NRAS mRNA	25562108
D003630	Daunorubicin	Daunorubicin results in increased expression of NRAS mRNA	12656675
D003840	Deoxycholic Acid	NRAS affects the reaction [Deoxycholic Acid results in increased expression of CEBPB]	18444174
D003840	Deoxycholic Acid	NRAS affects the reaction [Deoxycholic Acid results in increased expression of PTGS2]	18444174
D016190	Carboplatin	Carboplatin results in decreased expression of NRAS mRNA	18172885
C012279	dibutylnitrosamine	dibutylnitrosamine results in increased activity of NRAS	3040652
D004008	Diclofenac	Diclofenac affects the expression of NRAS mRNA	24752500
C000944	dicrotophos	dicrotophos results in decreased expression of NRAS mRNA	28302478
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of NRAS mRNA	26464624
D004052	Diethylnitrosamine	bicyclol inhibits the reaction [Diethylnitrosamine results in increased expression of NRAS mRNA]	17106253
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of NRAS mRNA	17106253
D004147	Dioxins	Dioxins affects the expression of NRAS mRNA	20463971
D004221	Disulfiram	[Disulfiram binds to Copper] which results in decreased expression of NRAS mRNA	24690739
D004365	Drugs, Chinese Herbal	"Drugs, Chinese Herbal results in decreased expression of NRAS mRNA"	12747207
D005419	Flavonoids	Flavonoids results in increased expression of NRAS mRNA	18035473
C574276	GDC-0973	NRAS protein mutant form results in increased susceptibility to GDC-0973	22084396
D019833	Genistein	Genistein results in increased expression of NRAS mRNA	24967385
D019833	Genistein	[Genistein co-treated with Methoxychlor] results in increased expression of NRAS mRNA	21782745
D019833	Genistein	Genistein results in increased expression of NRAS mRNA	21782745
C466792	GGTI 2147	GGTI 2147 promotes the reaction [L 744832 results in decreased prenylation of NRAS protein]	16156861
D005947	Glucose	[INS protein co-treated with Glucose] results in increased expression of NRAS mRNA	22634610
C031927	hydroquinone	hydroquinone results in decreased expression of NRAS mRNA	26047893
C096898	L 744832	GGTI 2147 promotes the reaction [L 744832 results in decreased prenylation of NRAS protein]	16156861
C096898	L 744832	L 744832 results in decreased prenylation of NRAS protein	16156861
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of NRAS mRNA	10975854
D008148	Lovastatin	Lovastatin results in decreased prenylation of NRAS protein	16156861
C034244	matrine	matrine results in increased expression of NRAS mRNA	11489473
D008727	Methotrexate	NRAS gene mutant form results in increased susceptibility to Methotrexate	24688052
D008731	Methoxychlor	[Genistein co-treated with Methoxychlor] results in increased expression of NRAS mRNA	21782745
D008731	Methoxychlor	Methoxychlor results in increased expression of NRAS mRNA	21782745
D008770	Methylnitrosourea	Methylnitrosourea results in increased expression of NRAS mRNA	20965277
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of NRAS mRNA"	23634900
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in increased expression of NRAS mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of NRAS mRNA"	25554681
D009532	Nickel	Nickel results in increased expression of NRAS mRNA	24768652\|2558310
D009532	Nickel	Nickel results in increased expression of NRAS mRNA	20053437
C014707	nitrosobenzylmethylamine	nitrosobenzylmethylamine results in increased expression of NRAS mRNA	17616710
D052638	Particulate Matter	Particulate Matter results in increased expression of NRAS mRNA	24769257
D000068437	Pemetrexed	NRAS gene mutant form results in increased susceptibility to Pemetrexed	24688052
D010634	Phenobarbital	Phenobarbital results in decreased expression of NRAS mRNA	19162173
D010695	Phlorhizin	Phlorhizin results in decreased expression of NRAS mRNA	22538082
D010936	Plant Extracts	Plant Extracts results in increased expression of NRAS mRNA	23557933
C045950	propiconazole	propiconazole results in decreased expression of NRAS mRNA	21278054
D011794	Quercetin	Quercetin results in decreased expression of NRAS mRNA	10652438
D011794	Quercetin	Quercetin results in decreased expression of NRAS protein	10652438\|2130869
C059514	resveratrol	resveratrol results in increased expression of NRAS protein	25505154
C017947	sodium arsenite	sodium arsenite results in decreased expression of NRAS protein	24431212
C017947	sodium arsenite	sodium arsenite results in increased expression of NRAS protein	24431212
C017947	sodium arsenite	sodium arsenite results in decreased expression of NRAS mRNA	25270620
D012969	Sodium Fluoride	Choline inhibits the reaction [Sodium Fluoride results in decreased expression of NRAS mRNA]	27664006
D012969	Sodium Fluoride	Sodium Fluoride results in decreased expression of NRAS mRNA	27664006
C471405	sorafenib	sorafenib results in decreased expression of NRAS mRNA	26409325
D010042	Ouabain	Ouabain results in decreased expression of NRAS mRNA	28795476
D000952	Antigens, Polyomavirus Transforming	"Antigens, Polyomavirus Transforming results in increased expression of NRAS mRNA"	26680231
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of NRAS mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in decreased expression of NRAS mRNA	25975270
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of NRAS mRNA	28065790
D014241	Trichloroethylene	Trichloroethylene results in increased expression of NRAS mRNA	19448997
D014635	Valproic Acid	Valproic Acid affects the expression of NRAS mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of NRAS mRNA	23179753\|2718838
D014635	Valproic Acid	Valproic Acid results in decreased methylation of NRAS gene	29154799
D014640	Vancomycin	Vancomycin results in decreased expression of NRAS mRNA	18930951
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of NRAS gene	25560391
C551177	vemurafenib	NRAS protein mutant form affects the susceptibility to vemurafenib	27222248
C551177	vemurafenib	[NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein	27222248
C551177	vemurafenib	[NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein	27222248
C551177	vemurafenib	[NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein	27222248
D014810	Vitamin E	Vitamin E results in decreased expression of NRAS mRNA	19244175

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003924	GTPase activity	-	IEA	-
GO:0005515	protein binding	-	IPI	18641128 20080631 21478863
GO:0005525	GTP binding	-	IEA	-
GO:0044877	protein-containing complex binding	-	IDA	23209302

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000165	MAPK cascade	-	TAS	-
GO:0001938	positive regulation of endothelial cell proliferation	-	IMP	23619365
GO:0002223	stimulatory C-type lectin receptor signaling pathway	-	TAS	-
GO:0007265	Ras protein signal transduction	-	TAS	-
GO:0043312	neutrophil degranulation	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000139	Golgi membrane	-	IEA	-
GO:0005794	Golgi apparatus	-	IDA	21968647
GO:0005886	plasma membrane	-	TAS	-
GO:0016020	membrane	-	HDA	19946888
GO:0070062	extracellular exosome	-	HDA	20458337
GO:0070821	tertiary granule membrane	-	TAS	-

KEGG ID	KEGG Term
hsa04010	MAPK signaling pathway
hsa04012	ErbB signaling pathway
hsa04062	Chemokine signaling pathway
hsa04360	Axon guidance
hsa04370	VEGF signaling pathway
hsa04530	Tight junction
hsa04540	Gap junction
hsa04650	Natural killer cell mediated cytotoxicity
hsa04660	T cell receptor signaling pathway
hsa04662	B cell receptor signaling pathway
hsa04664	Fc epsilon RI signaling pathway
hsa04720	Long-term potentiation
hsa04722	Neurotrophin signaling pathway
hsa04730	Long-term depression
hsa04810	Regulation of actin cytoskeleton
hsa04910	Insulin signaling pathway
hsa04912	GnRH signaling pathway
hsa04916	Melanogenesis
hsa05160	Hepatitis C
hsa05200	Pathways in cancer
hsa05211	Renal cell carcinoma
hsa05213	Endometrial cancer
hsa05214	Glioma
hsa05215	Prostate cancer
hsa05216	Thyroid cancer
hsa05218	Melanoma
hsa05219	Bladder cancer
hsa05220	Chronic myeloid leukemia
hsa05221	Acute myeloid leukemia
hsa05223	Non-small cell lung cancer

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-112399	IRS-mediated signalling	IEA
R-HSA-112412	SOS-mediated signalling	IEA
R-HSA-1168372	Downstream signaling events of B Cell Receptor (BCR)	TAS
R-HSA-1169092	Activation of RAS in B cells	TAS
R-HSA-1226099	Signaling by FGFR in disease	TAS
R-HSA-1227986	Signaling by ERBB2	IEA
R-HSA-1227986	Signaling by ERBB2	TAS
R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	TAS
R-HSA-1236394	Signaling by ERBB4	TAS
R-HSA-1250196	SHC1 events in ERBB2 signaling	IEA
R-HSA-1250347	SHC1 events in ERBB4 signaling	TAS
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-1433557	Signaling by SCF-KIT	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-1643685	Disease	TAS
R-HSA-1643713	Signaling by EGFR in Cancer	TAS
R-HSA-166520	Signaling by NTRKs	IEA
R-HSA-166520	Signaling by NTRKs	TAS
R-HSA-167044	Signalling to RAS	IEA
R-HSA-167044	Signalling to RAS	TAS
R-HSA-168249	Innate Immune System	TAS
R-HSA-168256	Immune System	TAS
R-HSA-171007	p38MAPK events	TAS
R-HSA-171007	p38MAPK events	IEA
R-HSA-177929	Signaling by EGFR	TAS
R-HSA-179812	GRB2 events in EGFR signaling	TAS
R-HSA-180336	SHC1 events in EGFR signaling	TAS
R-HSA-186763	Downstream signal transduction	TAS
R-HSA-186797	Signaling by PDGF	TAS
R-HSA-187037	Signaling by NTRK1 (TRKA)	IEA
R-HSA-187037	Signaling by NTRK1 (TRKA)	TAS
R-HSA-187687	Signalling to ERKs	IEA
R-HSA-187687	Signalling to ERKs	TAS
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-194138	Signaling by VEGF	TAS
R-HSA-1963640	GRB2 events in ERBB2 signaling	TAS
R-HSA-1963640	GRB2 events in ERBB2 signaling	IEA
R-HSA-202733	Cell surface interactions at the vascular wall	TAS
R-HSA-210993	Tie2 Signaling	TAS
R-HSA-2172127	DAP12 interactions	TAS
R-HSA-2179392	EGFR Transactivation by Gastrin	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	IEA
R-HSA-2424491	DAP12 signaling	TAS
R-HSA-2428924	IGF1R signaling cascade	IEA
R-HSA-2428928	IRS-related events triggered by IGF1R	IEA
R-HSA-2428933	SHC-related events triggered by IGF1R	IEA
R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	TAS
R-HSA-2871796	FCERI mediated MAPK activation	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-375165	NCAM signaling for neurite out-growth	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-416476	G alpha (q) signalling events	TAS
R-HSA-422475	Axon guidance	TAS
R-HSA-4420097	VEGFA-VEGFR2 Pathway	TAS
R-HSA-5218921	VEGFR2 mediated cell proliferation	TAS
R-HSA-5621481	C-type lectin receptors (CLRs)	TAS
R-HSA-5621575	CD209 (DC-SIGN) signaling	TAS
R-HSA-5637810	Constitutive Signaling by EGFRvIII	TAS
R-HSA-5637812	Signaling by EGFRvIII in Cancer	TAS
R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	TAS
R-HSA-5654687	Downstream signaling of activated FGFR1	TAS
R-HSA-5654688	SHC-mediated cascade:FGFR1	TAS
R-HSA-5654693	FRS-mediated FGFR1 signaling	TAS
R-HSA-5654696	Downstream signaling of activated FGFR2	TAS
R-HSA-5654699	SHC-mediated cascade:FGFR2	TAS
R-HSA-5654700	FRS-mediated FGFR2 signaling	TAS
R-HSA-5654704	SHC-mediated cascade:FGFR3	TAS
R-HSA-5654706	FRS-mediated FGFR3 signaling	TAS
R-HSA-5654708	Downstream signaling of activated FGFR3	TAS
R-HSA-5654712	FRS-mediated FGFR4 signaling	TAS
R-HSA-5654716	Downstream signaling of activated FGFR4	TAS
R-HSA-5654719	SHC-mediated cascade:FGFR4	TAS
R-HSA-5654736	Signaling by FGFR1	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5654741	Signaling by FGFR3	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	TAS
R-HSA-5655291	Signaling by FGFR4 in disease	TAS
R-HSA-5655302	Signaling by FGFR1 in disease	TAS
R-HSA-5655332	Signaling by FGFR3 in disease	TAS
R-HSA-5658442	Regulation of RAS by GAPs	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5673000	RAF activation	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5674135	MAP2K and MAPK activation	TAS
R-HSA-5675221	Negative regulation of MAPK pathway	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6798695	Neutrophil degranulation	TAS
R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	TAS
R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	TAS
R-HSA-6802949	Signaling by RAS mutants	TAS
R-HSA-6802952	Signaling by BRAF and RAF fusions	TAS
R-HSA-6802953	RAS signaling downstream of NF1 loss-of-function variants	TAS
R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	TAS
R-HSA-6802957	Oncogenic MAPK signaling	TAS
R-HSA-6806834	Signaling by MET	TAS
R-HSA-74751	Insulin receptor signalling cascade	IEA
R-HSA-74752	Signaling by Insulin receptor	IEA
R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	TAS
R-HSA-8848021	Signaling by PTK6	TAS
R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	TAS
R-HSA-8851805	MET activates RAS signaling	TAS
R-HSA-8853334	Signaling by FGFR3 fusions in cancer	TAS
R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	TAS
R-HSA-9006115	Signaling by NTRK2 (TRKB)	IEA
R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	IEA
R-HSA-9026519	Activated NTRK2 signals through RAS	IEA
R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	IEA
R-HSA-983705	Signaling by the B Cell Receptor (BCR)	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
27262212	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug)	Noonan SA	J Thorac Oncol
9347094	Effect of pyridostigmine on the thyroid-stimulating hormone response to thyrotropin-releasing hormone in abstinent alcoholics. (1997 Oct)	Coiro V	Alcohol Clin Exp Res
25351745	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15)	Arcila ME	Clin Cancer Res
12468438	CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. (2003 Apr 1)	Bowen DT	Blood
2072410	Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. (1991 Jul 17)	Slebos RJ	J Natl Cancer Inst
23515407	Characteristics of lung cancers harboring NRAS mutations. (2013 May 1)	Ohashi K	Clin Cancer Res
25738220	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May)	Sholl LM	J Thorac Oncol
15674422	RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. (2005 Mar)	Wiemels JL	Leukemia
24571676	RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures. (2014 Feb 26)	Andrade FG	BMC Cancer
28325255	Mucosal melanoma of the head and neck. (2017 Apr)	Ascierto PA	Crit Rev Oncol Hematol
28476195	Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia. (2016 Nov)	Kaur M	Arch Med Res
24055406	Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. (2013 Nov)	Hosgood HD 3rd	Respir Med
17932768	Effect of acetaldehyde upon cathepsin G and chymase. NRAS implications. (2008 May)	Brecher AS	Dig Dis Sci
27033383	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8)	Chen LF	Zhonghua Bing Li Xue Za Zhi
29083024	Pulmonary Langerhans' cell histiocytosis in adults. (2017)	Radzikowska E	Adv Respir Med
22975805	The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov)	Seo JS	Genome Res
26116372	MiR-21: an environmental driver of malignant melanoma? (2015 Jun 27)	Melnik BC	J Transl Med
27565922	Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep)	Maki-Nevala S	Lung Cancer
26860843	Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer. (2016 Oct)	Nicos M	Clin Transl Oncol
25567908	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15)	Drilon A	Clin Cancer Res
27258560	The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. (2018 Feb)	Skalova A	Appl Immunohistochem Mol Morphol